2-(nitrooxy)ethyl apovincaminate has been researched along with bupropion in 1 studies
*Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE. [MeSH]
*Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE. [MeSH]
| Studies (2-(nitrooxy)ethyl apovincaminate) | Trials (2-(nitrooxy)ethyl apovincaminate) | Recent Studies (post-2010) (2-(nitrooxy)ethyl apovincaminate) | Studies (bupropion) | Trials (bupropion) | Recent Studies (post-2010) (bupropion) |
|---|---|---|---|---|---|
| 20 | 1 | 1 | 3,392 | 755 | 1,329 |
| Protein | Taxonomy | 2-(nitrooxy)ethyl apovincaminate (IC50) | bupropion (IC50) |
|---|---|---|---|
| Acetylcholine receptor subunit alpha | Homo sapiens (human) | 5.2693 | |
| Acetylcholine receptor subunit gamma | Homo sapiens (human) | 5.2693 | |
| Integrin alpha-5 | Homo sapiens (human) | 1.8 | |
| Acetylcholine receptor subunit beta | Homo sapiens (human) | 5.2693 | |
| Neuronal acetylcholine receptor subunit beta-2 | Homo sapiens (human) | 0.9373 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.2003 | |
| Neuronal acetylcholine receptor subunit beta-4 | Homo sapiens (human) | 1.2028 | |
| Neuronal acetylcholine receptor subunit alpha-3 | Homo sapiens (human) | 1.367 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 1.9983 | |
| Neuronal acetylcholine receptor subunit alpha-7 | Homo sapiens (human) | 7.9 | |
| Neuronal acetylcholine receptor subunit alpha-4 | Homo sapiens (human) | 0.0135 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 1.0848 | |
| Acetylcholine receptor subunit delta | Homo sapiens (human) | 5.2693 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Babilonia, MB; Bower, J; Cole, S; Culakova, E; Desta, Z; Han, HS; Heckler, C; Hoogland, AI; Janelsins, M; Jim, HSL; Morrow, G; Peppone, L; Williams, GC | 1 |
1 trial(s) available for 2-(nitrooxy)ethyl apovincaminate and bupropion
| Article | Year |
|---|---|
A randomized placebo-controlled trial of bupropion for Cancer-related fatigue: Study design and procedures.
Topics: Age Factors; Antidepressive Agents, Second-Generation; Breast Neoplasms; Bupropion; Cancer Survivors; Cytochrome P-450 CYP2B6; Delayed-Action Preparations; Depression; Double-Blind Method; Fatigue; Female; Health Behavior; Humans; Menopause; Quality of Life; Research Design; Socioeconomic Factors; Vinca Alkaloids | 2020 |